Pentraxin  ||| S:0 E:10 ||| NNP
3  ||| S:10 E:12 ||| CD
in  ||| S:12 E:15 ||| IN
children  ||| S:15 E:24 ||| NNS
suffering  ||| S:24 E:34 ||| VBG
from  ||| S:34 E:39 ||| IN
allergic  ||| S:39 E:48 ||| JJ
rhinitis  ||| S:48 E:57 ||| JJ
Allergic  ||| S:57 E:66 ||| JJ
disorders  ||| S:66 E:76 ||| NNS
are  ||| S:76 E:80 ||| VBP
typically  ||| S:80 E:90 ||| RB
characterized  ||| S:90 E:104 ||| VBN
by  ||| S:104 E:107 ||| IN
an  ||| S:107 E:110 ||| DT
inflammatory  ||| S:110 E:123 ||| JJ
response  ||| S:123 E:132 ||| NN
to  ||| S:132 E:135 ||| TO
allergen  ||| S:135 E:144 ||| VB
exposure ||| S:144 E:152 ||| NN
.  ||| S:152 E:154 ||| .
PTX3  ||| S:154 E:159 ||| NNP
behaves  ||| S:159 E:167 ||| VBZ
as  ||| S:167 E:170 ||| IN
an  ||| S:170 E:173 ||| DT
acute-phase  ||| S:173 E:185 ||| JJ
response  ||| S:185 E:194 ||| NN
protein  ||| S:194 E:202 ||| NN
as  ||| S:202 E:205 ||| IN
there  ||| S:205 E:211 ||| EX
is  ||| S:211 E:214 ||| VBZ
a  ||| S:214 E:216 ||| DT
relationship  ||| S:216 E:229 ||| NN
between  ||| S:229 E:237 ||| IN
PTX3  ||| S:237 E:242 ||| CD
plasma  ||| S:242 E:249 ||| CD
levels  ||| S:249 E:256 ||| NNS
and  ||| S:256 E:260 ||| CC
disease  ||| S:260 E:268 ||| NN
severity ||| S:268 E:276 ||| NN
.  ||| S:276 E:278 ||| .
Therefore ||| S:278 E:287 ||| RB
,  ||| S:287 E:289 ||| ,
this  ||| S:289 E:294 ||| DT
study  ||| S:294 E:300 ||| NN
was  ||| S:300 E:304 ||| VBD
designed  ||| S:304 E:313 ||| VBN
to  ||| S:313 E:316 ||| TO
investigate  ||| S:316 E:328 ||| VB
a  ||| S:328 E:330 ||| DT
possible  ||| S:330 E:339 ||| JJ
role  ||| S:339 E:344 ||| NN
of  ||| S:344 E:347 ||| IN
PTX3  ||| S:347 E:352 ||| CD
in  ||| S:352 E:355 ||| IN
children  ||| S:355 E:364 ||| NNS
with  ||| S:364 E:369 ||| IN
allergic  ||| S:369 E:378 ||| JJ
rhinitis ||| S:378 E:386 ||| NN
.  ||| S:386 E:388 ||| .
One  ||| S:388 E:392 ||| CD
hundred  ||| S:392 E:400 ||| CD
patients  ||| S:400 E:409 ||| NNS
( ||| S:409 E:410 ||| -LRB-
28  ||| S:410 E:413 ||| CD
females ||| S:413 E:420 ||| NNS
,  ||| S:420 E:422 ||| ,
72  ||| S:422 E:425 ||| CD
males ||| S:425 E:430 ||| NNS
,  ||| S:430 E:432 ||| ,
median  ||| S:432 E:439 ||| JJ
age  ||| S:439 E:443 ||| NN
11  ||| S:443 E:446 ||| CD
years ||| S:446 E:451 ||| NNS
)  ||| S:451 E:453 ||| -RRB-
were  ||| S:453 E:458 ||| VBD
enrolled  ||| S:458 E:467 ||| VBN
in  ||| S:467 E:470 ||| IN
the  ||| S:470 E:474 ||| DT
study ||| S:474 E:479 ||| NN
.  ||| S:479 E:481 ||| .
All  ||| S:481 E:485 ||| DT
patients  ||| S:485 E:494 ||| NNS
were  ||| S:494 E:499 ||| VBD
monosensitized ||| S:499 E:513 ||| VBN
:  ||| S:513 E:515 ||| :
43  ||| S:515 E:518 ||| CD
( ||| S:518 E:519 ||| -LRB-
43 ||| S:519 E:521 ||| CD
% ||| S:521 E:522 ||| NN
)  ||| S:522 E:524 ||| -RRB-
to  ||| S:524 E:527 ||| TO
seasonal  ||| S:527 E:536 ||| JJ
allergens  ||| S:536 E:546 ||| NNS
( ||| S:546 E:547 ||| -LRB-
Graminaceae ||| S:547 E:558 ||| NNP
) ||| S:558 E:559 ||| -RRB-
,  ||| S:559 E:561 ||| ,
57  ||| S:561 E:564 ||| CD
( ||| S:564 E:565 ||| -LRB-
57 ||| S:565 E:567 ||| CD
% ||| S:567 E:568 ||| NN
)  ||| S:568 E:570 ||| -RRB-
to  ||| S:570 E:573 ||| TO
perennial  ||| S:573 E:583 ||| JJ
allergens  ||| S:583 E:593 ||| NNS
( ||| S:593 E:594 ||| -LRB-
house  ||| S:594 E:600 ||| NN
dust  ||| S:600 E:605 ||| NN
mites ||| S:605 E:610 ||| NNS
,  ||| S:610 E:612 ||| ,
cat  ||| S:612 E:616 ||| NN
and  ||| S:616 E:620 ||| CC
dog  ||| S:620 E:624 ||| NN
epithelium ||| S:624 E:634 ||| NN
,  ||| S:634 E:636 ||| ,
alternaria  ||| S:636 E:647 ||| JJ
tenuis ||| S:647 E:653 ||| NN
) ||| S:653 E:654 ||| -RRB-
.  ||| S:654 E:656 ||| .
Patients ||| S:656 E:664 ||| NNS
'  ||| S:664 E:666 ||| POS
blood  ||| S:666 E:672 ||| NN
samples  ||| S:672 E:680 ||| NNS
for  ||| S:680 E:684 ||| IN
assessing  ||| S:684 E:694 ||| VBG
serum  ||| S:694 E:700 ||| CD
PTX3  ||| S:700 E:705 ||| CD
levels  ||| S:705 E:712 ||| NNS
were  ||| S:712 E:717 ||| VBD
performed  ||| S:717 E:727 ||| VBN
during  ||| S:727 E:734 ||| IN
the  ||| S:734 E:738 ||| DT
spring ||| S:738 E:744 ||| NN
.  ||| S:744 E:746 ||| .
Children  ||| S:746 E:755 ||| NNS
with  ||| S:755 E:760 ||| IN
rhinitis  ||| S:760 E:769 ||| NN
had  ||| S:769 E:773 ||| VBD
higher  ||| S:773 E:780 ||| JJR
PTX3  ||| S:780 E:785 ||| NN
levels  ||| S:785 E:792 ||| NNS
and  ||| S:792 E:796 ||| CC
there  ||| S:796 E:802 ||| EX
was  ||| S:802 E:806 ||| VBD
a  ||| S:806 E:808 ||| DT
significant  ||| S:808 E:820 ||| JJ
relationship  ||| S:820 E:833 ||| NN
between  ||| S:833 E:841 ||| IN
symptom  ||| S:841 E:849 ||| JJ
severity  ||| S:849 E:858 ||| NN
and  ||| S:858 E:862 ||| CC
serum  ||| S:862 E:868 ||| JJ
levels ||| S:868 E:874 ||| NNS
.  ||| S:874 E:876 ||| .
Therefore ||| S:876 E:885 ||| RB
,  ||| S:885 E:887 ||| ,
this  ||| S:887 E:892 ||| DT
study  ||| S:892 E:898 ||| NN
shows  ||| S:898 E:904 ||| NNS
that  ||| S:904 E:909 ||| IN
PTX3  ||| S:909 E:914 ||| CD
serum  ||| S:914 E:920 ||| CD
levels  ||| S:920 E:927 ||| NNS
could  ||| S:927 E:933 ||| MD
be  ||| S:933 E:936 ||| VB
a  ||| S:936 E:938 ||| DT
reliable  ||| S:938 E:947 ||| JJ
marker  ||| S:947 E:954 ||| NN
for  ||| S:954 E:958 ||| IN
symptom  ||| S:958 E:966 ||| JJ
severity  ||| S:966 E:975 ||| NN
in  ||| S:975 E:978 ||| IN
children  ||| S:978 E:987 ||| NNS
with  ||| S:987 E:992 ||| IN
allergic  ||| S:992 E:1001 ||| JJ
rhinitis ||| S:1001 E:1009 ||| NN
.  ||| S:1009 E:1011 ||| .
